Alpha-adrenergic blockers and central alpha-2 agonists
Two groups of medicines that lower blood pressure through the alpha-adrenergic system. The alpha blockers block alpha-adrenergic receptors; MeSH says they are used in high blood pressure, vasospasm, peripheral vascular disease, shock and pheochromocytoma. The central alpha-2 agonists act through the central nervous system. The US labels read for one of each list high blood pressure, and the alpha blocker label lists prostate enlargement as well.
Also called Alpha blockers · Adrenergic alpha-antagonists · Central alpha-2 agonists
- Drug
- In this atlas
Overview
Technical summary
Class page for two related groups, written as one because the plan combined them. MeSH descriptors D000317 (Adrenergic alpha-Antagonists, last updated 2018-06-14) and D058647 (Adrenergic alpha-2 Receptor Agonists, last updated 2011-01-01) are both broad matches, because neither alone is the whole page. Two US labels were read. CARDURA (doxazosin tablets, application NDA019668, effective 2023-10-15 in openFDA) calls the medicine an alpha 1 adrenergic antagonist and lists benign prostatic hyperplasia and hypertension. Catapres-TTS (clonidine transdermal system, application NDA018891, effective 2026-01-06 in openFDA) is indicated for hypertension, describes clonidine as a centrally acting agent, and the openFDA record gives the established pharmacologic class Central alpha-2 Adrenergic Agonist. The second MeSH scope note is only one sentence. This page gives no dose, no trial result and no guideline statement; no warning in either label was recorded. Medicines of the groups that have their own pages are filed under it.
Drugs in this class
1 drug in this atlas is filed under Alpha-adrenergic blockers and central alpha-2 agonists, with the registry trials and FDA regulatory decisions this atlas holds for each. With Alpha-adrenergic blockers and central alpha-2 agonists itself, the class has 0 distinct trials and 0 distinct FDA decisions; a trial or decision that two of them share counts once there.
About this drug
- Level
- Class
- Mechanism
- MeSH says alpha-antagonists bind to alpha-adrenergic receptors without activating them, and so block the actions of adrenergic agonists. A US label says clonidine reduces sympathetic outflow from the central nervous system.
Classification codes
-
D000317Adrenergic alpha-Antagonists -
D058647Adrenergic alpha-2 Receptor Agonists
Claims and evidence
Context People with hypertension, and men with benign prostatic hyperplasia for the alpha blocker, as described in two US labels
- Recipient
- Recipient not specified
- Population
- Patients described in the indications sections of the two labels: patients with hypertension, and for the alpha blocker label also patients with the signs and symptoms of benign prostatic hyperplasia.
- Care setting
- Prescription medicine, as described in the US labels
- Geography
- United States (US drug labels)
- Life stage
- Not stated in the passages read
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 2 inclusion criteria; exclusion criteria not stated
- Included
- Hypertension
- Signs and symptoms of benign prostatic hyperplasia (alpha blocker label only)
- Excluded
- None stated
Two US labels were read. The label of CARDURA (doxazosin tablets, Viatris Specialty LLC, application NDA019668; the version dated 2023-10-15 in openFDA) calls the medicine an alpha 1 adrenergic antagonist and lists the signs and symptoms of benign prostatic hyperplasia and the treatment of hypertension. The label of Catapres-TTS (clonidine transdermal system, Technomed Inc., application NDA018891; the version dated 2026-01-06 in openFDA) says it is indicated in the treatment of hypertension and describes clonidine as a centrally acting agent; openFDA's record gives the established pharmacologic class Central alpha-2 Adrenergic Agonist. MeSH says alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock and pheochromocytoma.
Applies to Recipient not specified People with hypertension, and men with benign prostatic hyperplasia for the alpha blocker, as described in two US labels
- Certainty method
- Not assessed
- Limitations
- This claim records what two US labels say. It is not a finding about how well either medicine works, and no trial result is recorded for it in this atlas. The prostate indication belongs to the alpha blocker label only. The pharmacologic class name for the second medicine comes from openFDA's record of its label. The second label is for a skin patch; an oral form of the same medicine was not read. Contraindications, warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-09
- Next evidence check due
- Not scheduled
Sources and citations (6)
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
- How it applies
- Alpha 1 adrenergic antagonist; BPH and hypertension.
- Retrieved
- Source effective date
- 2023-10-15
- Source state
- Current
- Version fingerprint
2493e9d5346ff8f7d721f288aecee512a7d67a1a821ff0bc5d51ecc0e171f615- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20231015.
- Retrieved
- Source effective date
- 2023-10-15
- Source state
- Current
- Version fingerprint
2493e9d5346ff8f7d721f288aecee512a7d67a1a821ff0bc5d51ecc0e171f615- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], INDICATIONS AND USAGE
- How it applies
- Hypertension use of the clonidine patch.
- Retrieved
- Source effective date
- 2026-01-06
- Source state
- Current
- Version fingerprint
25b034f47f06bcd1ee51201e6a4304164ccc881c2f64f9b3b48af68ba3e7be66- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].openfda.pharm_class_epc[0]
- How it applies
- Established pharmacologic class in openFDA: Central alpha-2 Adrenergic Agonist.
- Retrieved
- Source effective date
- 2026-01-06
- Source state
- Current
- Version fingerprint
25b034f47f06bcd1ee51201e6a4304164ccc881c2f64f9b3b48af68ba3e7be66- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20260106.
- Retrieved
- Source effective date
- 2026-01-06
- Source state
- Current
- Version fingerprint
25b034f47f06bcd1ee51201e6a4304164ccc881c2f64f9b3b48af68ba3e7be66- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
Supports MeSH scope note for descriptor D000317 (Adrenergic alpha-Antagonists)
- Locator
- scopeNote.@value
- How it applies
- MeSH scope note: uses of alpha-antagonists.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
5e459df894b106c7bfd5f9d8996b03f3c29594b42073a810102193c01b8cfc4c- Reuse basis
- The NLM web policies page (sha256 c8b7026b5c3fcfd1b0cb88755077f6a99a5f2159eecd42b0e7d1a5ad9b30ec55, hash only) says works produced by the U.S. government are not subject to copyright protection in the United States and asks users to acknowledge NLM as the source. Source: National Library of Medicine. This copy was fetched on 2026-11-09 and may not reflect the most current data. The raw bytes are committed in the atlas repository.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact Two US labels list treating high blood pressure as an indication: Hypertension (high blood pressure)
Applies to Recipient not specified People with hypertension, and men with benign prostatic hyperplasia for the alpha blocker, as described in two US labels
Two US labels were read. The label of CARDURA (doxazosin tablets, Viatris Specialty LLC, application NDA019668; the version dated 2023-10-15 in openFDA) calls the medicine an alpha 1 adrenergic antagonist and lists the signs and symptoms of benign prostatic hyperplasia and the treatment of hypertension. The label of Catapres-TTS (clonidine transdermal system, Technomed Inc., application NDA018891; the version dated 2026-01-06 in openFDA) says it is indicated in the treatment of hypertension and describes clonidine as a centrally acting agent; openFDA's record gives the established pharmacologic class Central alpha-2 Adrenergic Agonist. MeSH says alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock and pheochromocytoma.Limitations. This claim records what two US labels say. It is not a finding about how well either medicine works, and no trial result is recorded for it in this atlas. The prostate indication belongs to the alpha blocker label only. The pharmacologic class name for the second medicine comes from openFDA's record of its label. The second label is for a skin patch; an oral form of the same medicine was not read. Contraindications, warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Record details
- Record id
cardio:alpha-adrenergic-blockers-and-central-alpha-2-agonists- Content hash
9909b795268356a22ed4e507ad06a749666b660a7d7468dc8f55787bb8affa9a